Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 8/2010

01-08-2010 | Original Article

Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma

Authors: Esther Kamphausen, Christiane Kellert, Tarish Abbas, Nadja Akkad, Stefan Tenzer, Graham Pawelec, Hansjoerg Schild, Peter van Endert, Barbara Seliger

Published in: Cancer Immunology, Immunotherapy | Issue 8/2010

Login to get access

Abstract

Immune surveillance of tumour cells by CD8+ cytotoxic T cells plays a key role in the establishment and control of an anti-tumour response. This process requires the generation of antigenic peptides, which are largely produced by the proteasome in combination with other proteases located in either the cytoplasm and/or the endoplasmic reticulum (ER). The ER-resident aminopeptidases ERAP1 and ERAP2 trim or even destroy HLA class I-binding peptides thereby shaping the peptide repertoire presented for T cell recognition. So far there exists limited information about the expression pattern of ERAP1 and/or ERAP2 in human tumours of distinct histotypes. Therefore, the expression profiles and modes of regulation of both aminopeptidases were determined in a large series of melanoma cell lines. A heterogeneous expression ranging from high to reduced or even total loss of ERAP1 and/or ERAP2 mRNA and/or protein expression was detected, which often could be induced/upregulated by interferon-γ treatment. The observed altered ERAP1 and/or ERAP2 expression and activity levels were either mediated by sequence alterations affecting the promoter or enzymatic activities, leading to either transcriptional and/or post-transcriptional downregulation mechanisms or limited or excessive processing activities, which both might have an impact on the antigenic peptide repertoire presented on HLA class I molecules.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Yewdell JW (2005) The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 207:8–18CrossRefPubMed Yewdell JW (2005) The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 207:8–18CrossRefPubMed
3.
go back to reference Hammer GE, Kanaseki T, Shastri N (2007) The final touches make perfect the peptide-MHC class I repertoire. Immunity 26:397–406CrossRefPubMed Hammer GE, Kanaseki T, Shastri N (2007) The final touches make perfect the peptide-MHC class I repertoire. Immunity 26:397–406CrossRefPubMed
4.
go back to reference Goldberg AL, Cascio P, Saric T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147–164CrossRefPubMed Goldberg AL, Cascio P, Saric T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147–164CrossRefPubMed
5.
go back to reference Saveanu L, Carroll O, Hassainya Y, van Endert P (2005) Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation. Immunol Rev 207:42–59CrossRefPubMed Saveanu L, Carroll O, Hassainya Y, van Endert P (2005) Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation. Immunol Rev 207:42–59CrossRefPubMed
6.
go back to reference Levy F, Burri L, Morel S et al (2002) The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J Immunol 169:4161–4171PubMed Levy F, Burri L, Morel S et al (2002) The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J Immunol 169:4161–4171PubMed
7.
go back to reference Endert P (2008) Role of tripeptidyl peptidase II in MHC class I antigen processing—the end of controversies. Eur J Immunol 38:609–613CrossRefPubMed Endert P (2008) Role of tripeptidyl peptidase II in MHC class I antigen processing—the end of controversies. Eur J Immunol 38:609–613CrossRefPubMed
8.
go back to reference Rock KL, York IA, Goldberg AL (2004) Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5:670–677CrossRefPubMed Rock KL, York IA, Goldberg AL (2004) Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5:670–677CrossRefPubMed
9.
go back to reference Stoltze L, Schirle M, Schwarz G et al (2000) Two new proteases in the MHC class I processing pathway. Nat Immunol 5:413–418CrossRef Stoltze L, Schirle M, Schwarz G et al (2000) Two new proteases in the MHC class I processing pathway. Nat Immunol 5:413–418CrossRef
10.
go back to reference Hammer GE, Gonzalez F, James E, Nolla H, Shastri N (2007) In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat Immunol 8:101–108CrossRefPubMed Hammer GE, Gonzalez F, James E, Nolla H, Shastri N (2007) In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat Immunol 8:101–108CrossRefPubMed
11.
go back to reference Chang SC, Momburg F, Bhutani N, Goldberg AL (2006) The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci USA 102:17107–17112CrossRef Chang SC, Momburg F, Bhutani N, Goldberg AL (2006) The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci USA 102:17107–17112CrossRef
12.
go back to reference Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N (2006) The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7:103–112CrossRefPubMed Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N (2006) The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7:103–112CrossRefPubMed
13.
go back to reference Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848CrossRefPubMed Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848CrossRefPubMed
14.
go back to reference Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69 Suppl 1:264–268CrossRefPubMed Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69 Suppl 1:264–268CrossRefPubMed
15.
go back to reference Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129–138CrossRefPubMed Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129–138CrossRefPubMed
16.
go back to reference Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMed Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMed
17.
go back to reference Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197–206CrossRefPubMed Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197–206CrossRefPubMed
18.
go back to reference Fruci D, Giacomini P, Nicotra MR et al (2008) Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol 216:742–749CrossRefPubMed Fruci D, Giacomini P, Nicotra MR et al (2008) Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol 216:742–749CrossRefPubMed
19.
go back to reference Fruci D, Ferracuti S, Limongi MZ et al (2006) Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol 176:4869–4879PubMed Fruci D, Ferracuti S, Limongi MZ et al (2006) Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol 176:4869–4879PubMed
20.
go back to reference Varona A, Blanco L, Lopez JI et al (2007) Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 292:F780–F788CrossRefPubMed Varona A, Blanco L, Lopez JI et al (2007) Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 292:F780–F788CrossRefPubMed
21.
go back to reference Mehta AM, Jordanova ES, van Wezel T et al (2007) Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 46:577–586CrossRefPubMed Mehta AM, Jordanova ES, van Wezel T et al (2007) Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 46:577–586CrossRefPubMed
22.
go back to reference Schatz MM, Peters B, Akkad N et al (2008) Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol 180:3210–3217PubMed Schatz MM, Peters B, Akkad N et al (2008) Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol 180:3210–3217PubMed
23.
go back to reference Reits E, Neijssen J, Herberts C et al (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495–506CrossRefPubMed Reits E, Neijssen J, Herberts C et al (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495–506CrossRefPubMed
24.
go back to reference Cui X, Rouhani FN, Hawari F, Levine SJ (2003) Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 171:6814–6819PubMed Cui X, Rouhani FN, Hawari F, Levine SJ (2003) Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 171:6814–6819PubMed
25.
go back to reference Akada T, Yamazaki T, Miyashita H et al (2002) Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is involved in the activation of endothelial integrins. J Cell Physiol 193:253–262CrossRefPubMed Akada T, Yamazaki T, Miyashita H et al (2002) Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is involved in the activation of endothelial integrins. J Cell Physiol 193:253–262CrossRefPubMed
26.
go back to reference Shido F, Ito T, Nomura S et al (2006) Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology 147:1780–1788CrossRefPubMed Shido F, Ito T, Nomura S et al (2006) Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology 147:1780–1788CrossRefPubMed
27.
go back to reference Mehta AM, Jordanova ES, Corver WE et al (2009) Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer 48:410–418CrossRefPubMed Mehta AM, Jordanova ES, Corver WE et al (2009) Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer 48:410–418CrossRefPubMed
28.
go back to reference Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B (1999) Gene transfer of the co-stimulatory molecules B7–1 and B7–2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 50:242–249CrossRefPubMed Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B (1999) Gene transfer of the co-stimulatory molecules B7–1 and B7–2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 50:242–249CrossRefPubMed
29.
go back to reference Herrmann F, Trowsdale J, Huber C, Seliger B (2003) Cloning and functional analyses of the mouse tapasin promoter. Immunogenetics 55:379–388CrossRefPubMed Herrmann F, Trowsdale J, Huber C, Seliger B (2003) Cloning and functional analyses of the mouse tapasin promoter. Immunogenetics 55:379–388CrossRefPubMed
30.
go back to reference Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B (2004) Downregulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma. J Urol 171:885–889CrossRefPubMed Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B (2004) Downregulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma. J Urol 171:885–889CrossRefPubMed
31.
go back to reference Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I et al (2001) Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61:8647–8650PubMed Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I et al (2001) Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61:8647–8650PubMed
32.
go back to reference Kanaseki T, Blanchard N, Hammer GE, Gonzalez F, Shastri N (2006) ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulium. Immunity 25:795–806CrossRefPubMed Kanaseki T, Blanchard N, Hammer GE, Gonzalez F, Shastri N (2006) ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulium. Immunity 25:795–806CrossRefPubMed
Metadata
Title
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma
Authors
Esther Kamphausen
Christiane Kellert
Tarish Abbas
Nadja Akkad
Stefan Tenzer
Graham Pawelec
Hansjoerg Schild
Peter van Endert
Barbara Seliger
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 8/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0856-7

Other articles of this Issue 8/2010

Cancer Immunology, Immunotherapy 8/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine